# Efficacy of Faviprevir in COVID-19 Treatment

> **NCT04351295** · PHASE2,PHASE3 · COMPLETED · sponsor: **Tanta University** · enrollment: 92 (actual)

## Conditions studied

- COVID

## Interventions

- **DRUG:** Favipiravir
- **DRUG:** Chloroquine

## Key facts

- **NCT ID:** NCT04351295
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-20
- **Primary completion:** 2020-09-28
- **Final completion:** 2020-09-28
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2021-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04351295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04351295, "Efficacy of Faviprevir in COVID-19 Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04351295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*